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Abstract
Background: The presence of circulating anti-myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) has been
described in sera of patients with different inflammatory conditions of the central nervous system. In adults the
core clinical feature is usually characterised by acute myelitis and/or optic neuritis. We here report an atypical case
with serum and cerebrospinal fluid MOG-Abs and a clinical picture suggestive for acute encephalitis.
Case presentation: A 31-year-old Indian man presented with altered mental status, slight fever, and ataxia. Brain
magnetic resonance imaging noted a widespread involvement of the white matter associated with slight cortical
and subcortical damage in absence of contrast enhancement. An extensive infectious screening resulted negative
while autoimmune analysis revealed the presence of MOG-Abs, detected with live cell-based assay. After treatment
with intravenous immunoglobulins a marked and prompt clinical and radiological improvement was observed.
Conclusions: To date, several areas of uncertainty still remain regarding clinical features and prognosis of subjects
with MOG-Abs. The description of atypical cases is crucial, since recognition of this condition leads to prompt
treatment and better prognosis, as in the case here reported.
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Background
Anti-myelin oligodendrocyte glycoprotein antibodies
(MOG-Abs) have been reported in different inflamma-
tory demyelinating diseases as acute disseminated en-
cephalomyelitis (ADEM), neuromyelitis optica spectrum
disorders (NMOSD), idiopathic optic neuritis, idiopathic
myelitis, and atypical multiple sclerosis [1–13]. However,
the whole spectrum of clinical phenotypes associated
with MOG-Abs-related disorders has still to be clearly
defined. Here, we present a patient with MOG-Abs and
a clinical picture resembling infectious encephalitis as a
possible new clinical phenotype associated with these
antibodies.
Case presentation
A previously healthy 31-year-old Indian man presented
to the emergency room with confusion and altered con-
sciousness. Five days prior to onset of neurological
symptoms he developed slight fever (<38 °C), sore throat
and headache. His past medical history was unremark-
able except for a recent stay in India for 2 months.
Neurological examination disclosed a wide-based and
unsteady gait and reduced level of consciousness. Diffuse
papules and enanthema were also observed and spontan-
eously disappeared few days later. A slight increase of
erythrocyte and leukocyte cell counts (13.000 cells/μL),
erythrocyte sedimentation rate (30 mm/h) and C-reactive
protein (48 mg/l) was noted on basic laboratory test. The
patient was initially treated with acyclovir and ceftriaxone
for a presumptive diagnosis of infectious encephalitis. A
cerebrospinal fluid (CSF) analysis showed total protein
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level of 53 mg/dl, 179 cells/μL (90% mononuclear) in
absence of oligoclonal IgG bands. On brain magnetic
resonance imaging (MRI), fluid attenuated inversion
recovery (FLAIR) and T2 diffuse hyperintensities in-
volving thalamus, basal ganglia, internal capsule, me-
sial temporal lobes and brainstem associated with
small hyperintensities in the subcortical, periventricu-
lar and cortical regions were noted in absence of
contrast enhancement (Fig. 1a-d). Diffusion weighted
images showed a mild restrictive pattern of the
sopratentorial lesions affecting the left and right thal-
amus, the posterior limb of the internal capsule of
both sides, the splenium and the posterior profile of
the left trigonum. These lesions also presented
medium-high apparent diffusion coefficient values
and central core of low apparent diffusion coefficient,
suggesting an inflammatory process. Whole spinal
cord MRI was normal. A comprehensive workup for
viral encephalitis and atypical infections including
polymerase chain reaction for Human immunodefi-
ciency virus, Enterovirus, Herpes simplex 1–2-6,
Epstein-Barr, Cytomegalovirus, Varicella Zoster, Toxo-
plasma, Mycobacterium tuberculosis, Treponema pal-
lidum, Bartonella henselae, Human Parechovirus,
West Nile, Dengue, Chikungunya, and Japanese en-
cephalitis resulted negative and also cultures for bac-
teria and fungi. An extensive autoimmune screening
including anti-nuclear antibodies, complement levels,
thyroid function and antibodies, autoantibodies to
synaptic receptors and neuronal cell surface proteins
was also negative. The criteria for collagen diseases,
vasculitis, Behçet and Hashimoto encephalopathy were
not satisfied. No neuropil staining was observed on
tissue-based screening with immunohistochemistry on
rat sections. Testing for MOG-Abs with a live cell-
based assay with recombinant full-length MOG
expressed in HEK293 cells [14], identified MOG-Abs
both in the serum (titer of 1:5120) and in the CSF
(titer 1:8). Staining of rat brain tissue with serum and
CSF samples resulted in a specific myelin staining
already described for MOG-Abs as shown in Fig. 2
[15]. The patient was treated with intravenous im-
munoglobulin (IVIg) 0.5 g/kg/day for 5 days with an
almost complete clinical recovery in a few days. On
control MRI examination after 2 weeks a dramatic
improvement of pre-existing lesion was observed
(Fig. 1e-h). Only the persistence of slight unsteady
gait was noted at the last clinical evaluation 2 weeks
after the onset.
Discussion and conclusions
We here report an atypical presentation of MOG-Abs
associated disorder with a prompt response to IVIg
which satisfied the criteria of “possible encephalitis of
presumed infectious origin” which also was the main
presumptive clinical diagnosis [16]. Since the patient
Fig. 1 FLAIR sequence from the brain MRI at onset (a-d) and after treatment (e-h). Cortical and subcortical damage (a-b) with severe bilateral
involvement of thalamus and internal capsule (b), mesial temporal lobes (c) and pons (d) in absence of contrast enhancement, is seen on brain
MRI performed ad onset. After treatment with IVIg a significant improvement was noted with an almost complete resolution of the cortical,
thalamic and basal ganglia involvement (e-f) and a reduction of temporal (g) and brainstem lesions (h)
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presented with subacute onset of altered mental sta-
tus, new focal central nervous system findings and
CSF pleocytosis in absence of alternative causes, he
also met the revised diagnostic criteria for possible
autoimmune encephalitis recently proposed [17].
However, the absence of neuropil staining on immu-
nohistochemistry ruled out the presence of other well
defined auto-antibodies or overlapping syndromes. In
the case here reported, some features, as the multiple
sopratentorial lesions of the white matter, basal gan-
glia, thalamus and brainstem, resemble those observed
in ADEM. However, pleocytosis was higher than that
usually observed in patients with ADEM and MRI
was not totally compatible due to the type of gray
and periventricular involvement and the absence of
spinal cord lesions. Since criteria for ADEM have
been clearly established only for pediatric cases [18]
and the diagnosis in adults, also with MOG-Abs, re-
main challenging [17], we classified the case as “en-
cephalitis” rather than ADEM.
Only five cases of encephalitis with MOG-Abs have
been reported so far and are summarized in Table 1
[19, 20].
In these reports an autoimmune aetiology was the
main presumptive diagnosis while in the case here
described clinical and radiological data were suggest-
ive of an infectious process. Moreover, all the previ-
ously reported cases presented seizures at onset or
during the course of the disease and 3 out of 5 pa-
tients had optic neuritis, a feature clearly associated
with MOG-Abs. The radiological features here
described are also unique and in part different from
the ADEM-like [19] or unilateral cortical lesions [20]
previously reported. In these cases the onset was
characterised by an exclusive cortical damage and in
only one patient the involvement of corpus callosum,
cingulate gyrus, frontal lobes, midbrain, thalamus,
and nucleus basalis was noted during the follow-up
[19]. In our patient we observed at onset an exten-
sive involvement of the thalamus, basal ganglia, in-
ternal capsule, mesial temporal lobes and brainstem
associated with subcortical, periventricular and cor-
tical damage. Finally, the prompt response to IVIg is
also a peculiar finding, since the other cases had a
complete recovery after steroids treatment that led
to the definition of “steroid- responsive encephalitis
“[20]. The role of infectious agent in triggering
MOG-Abs production is still a matter of debate.
However, the flu-like symptoms here reported are
not unexpected since attacks are preceded by infec-
tions at least once in about 40% of MOG-Abs
positive cases [1]. The infection could also be re-
sponsible for the blood-brain barrier breakdown that
allows the entry of autoantibodies in the central ner-
vous system. This report confirms that MOG-Abs
might denote a disease entity in its own right and
that the spectrum of MOG-Abs associated diseases
is wider than NMOSD and ADEM. Since a prompt
and adequate treatment can lead to a favorable
outcome, clinicians should be aware of this condi-
tion, also in clinical pictures suggestive for infectious
encephalitis.
Fig. 2 Immunohistochemical analysis. Serum (dilution 1:100, MOG-IgG and IgG1 titer 1:5120, also reactive with rat and mouse MOG) and CSF
(dilution 1:2, MOG-ab titer 1:8) samples were screened by immunohistochemistry on a tissue-based assay (in-house; avidin-biotin-peroxidase
technique; rat brain) as described previously by Sepulveda et al. 2016 [15]. The CSF (diluted 1:2) showed a specific myelin staining in the
anterior commissure (a) and cerebellar white matter (b), whereas a control sample was negative (c, d). Magnification: A, C: ×100; B, D: ×60
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